HIV Policy Archives | Page 7 of 29

Online Event: Highlights from the Virtual AIDS 2020 Conference

Event Date: Jul 20, 2020

Event

Earlier this month, the International AIDS Conference – the world's largest conference on HIV and AIDS – took place on a virtual stage. Over five days, the conference showcased the latest research and analysis by leaders in the HIV sector. On Friday, July 24, the CSIS Global Health Policy Center and KFF (the Kaiser Family Foundation) held a public event to discuss the outcomes of the AIDS 2020 Virtual Conference. The discussion covered scientific developments, current HIV/AIDS funding levels, progress towards global…

Quantifying PEPFAR’s Role for Women and Girls: Analysis of Monitoring, Evaluation, and Reporting Indicator Data, 2016-2019

Jul 8, 2020

Feature

Women and girls represent more than half of all people living with HIV worldwide, and HIV is the leading cause of death among women aged 15-49. This analysis sought to quantify PEPFAR’s role for women and girls in key program areas, analyzing data over time as well as by country, to better understand the extent of its reach.

State Medicaid Management of Prescription Drugs for HIV Treatment and Prevention

Jun 4, 2020

Issue Brief

This data note, primarily based on a survey of state Medicaid pharmacies, reviews cost-containment policies and protections as they relate to antiretrovirals for treatment and prevention of HIV.

Managing HIV During COVID-19: Working to End One Epidemic While Confronting Another

Apr 13, 2020

Policy Watch

As the COVID-19 outbreak continues to grow in the United States, it threatens efforts to address existing health challenges, including the HIV/AIDS epidemic. This blog piece explores whether efforts to “end the HIV epidemic” can be sustained while confronting COVID-19, particularly as the very systems and workforce needed to address HIV are being stretched thin to confront the new crisis.

Quick Look: Antiretroviral Price Increases in Medicare Part D

Dec 17, 2019

Issue Brief

Drug price concerns in the U.S., including for antiretrovirals, the mainstay of HIV treatment and, increasingly prevention, have prompted the introduction of several policy proposals. One proposal would require manufacturers to provide a rebate to the federal government if prices increase faster than inflation. We assessed list price changes for ARVs under Part D, which is required to cover all or substantially all ARVs.

HIV, Intimate Partner Violence (IPV), and Women: An Emerging Policy Landscape

Dec 2, 2019

Issue Brief

Intimate partner violence has been shown to be associated with increased risk for HIV among women, as well as poorer treatment outcomes for those already diagnosed. This brief reviews the link between IPV and HIV, key policy changes and initiatives that attempt to address these challenges.

Insurance Coverage Among Non-elderly People with HIV, 2017

Sep 30, 2019

Feature

Insurance Coverage Among PWH 2017 – Non-Elderly PWH only Download

Insurance Coverage Among People with HIV and the General Population, Nonelderly Adults, 2015

May 20, 2019

Feature

Coverage Among People with HIV and the General Public Download

Rates of Viral Suppression Among Nonelderly Adults with HIV, by Coverage, 2015

May 20, 2019

Feature

Rates of Viral Suppresion by Coverage Download

Insurance Coverage Among Nonelderly Adults with HIV in Medicaid Expansion and Non-expansion States, 2015

May 20, 2019

Feature

Insurance Coverage Among People with HIV Expansion and Non-Expansion States Download

Topics

Policy Research

Polling

Health News

Data & Features

For Media

About

View the Latest: HIV Policy

Filter